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1. INTRODUCTION {#cam42281-sec-0005}
===============

Breast cancer (BC) is the most frequently diagnosed malignance among women and the one of the most common causes of cancer‐related death.[1](#cam42281-bib-0001){ref-type="ref"}, [2](#cam42281-bib-0002){ref-type="ref"} Clinical therapeutic strategies and prognosis of BC are based on tumor characteristics, patient factors and response to treatment. However, its high heterogeneity results in a broad range of clinical outcomes even among BC patients with similar clinical staging and pathologic grading.[3](#cam42281-bib-0003){ref-type="ref"} Tumor microenvironment, inflammation, and immune response have been reported to play important roles in tumor progression and prognosis.[4](#cam42281-bib-0004){ref-type="ref"}, [5](#cam42281-bib-0005){ref-type="ref"}

Recently, substantial evidence shown that inflammation‐based models, such as the systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR) and inflammation‐based index, were useful indicators for predicting the prognosis of various solid cancers.[6](#cam42281-bib-0006){ref-type="ref"}, [7](#cam42281-bib-0007){ref-type="ref"} NLR and PLR, two of the most frequently applied indicators, have been widely investigated for their value in predicting prognosis of BC patients. A majority of researches demonstrated elevated peripheral NLR and PLR were recognized as poor prognostic factors.[8](#cam42281-bib-0008){ref-type="ref"}, [9](#cam42281-bib-0009){ref-type="ref"} Nevertheless, there were still others revealed patients with elevated PLR were associated with better survival outcomes.[10](#cam42281-bib-0010){ref-type="ref"}

Therefore, this study was conducted to evaluate the prognostic value of NLR and PLR on overall survival (OS) and disease‐free survival (DFS) for BC patients. Moreover, by performing subgroup analyses, we quantified the effect of NLR and PLR in different subgroups.

2. METHODS {#cam42281-sec-0006}
==========

2.1. Search strategy {#cam42281-sec-0007}
--------------------

A comprehensive literature search of relevant studies was performed through the online medical databases PubMed, Embase, Web of Science, the Cochrane Library and Scopus. Studies focused on the correlation of BC and NLR as well as PLR were taken into retrievement. Search terms were confined to the following main words and Medical Subject Headings terms: "neutrophil", "platelet", "lymphocyte", "neutrophil‐to‐lymphocyte", "platelet‐to‐lymphocyte", "breast cancer", and "breast carcinoma". Moreover, by using cross‐references from the references of primary selected studies and relevant studies, a backward search was also performed to ensure a comprehensive search. Literatures were restricted to those written in English. There was no restriction on geographical region. Two reviewers (Wanying Guo and Xin Lu) completed the electronic search independently.

2.2. Study inclusion and exclusion criteria {#cam42281-sec-0008}
-------------------------------------------

Reviewers screened the eligible studies based upon inclusion and exclusion criteria which were prespecified. The final decision on inclusion and exclusion criteria were approved by all the authors. Any disagreements between the two reviewers were solved and made final decision by the senior reviewer (Miao Deng).

The criteria for inclusion were as following: Articles analyzed BC patients.Articles evaluated prognostic value of NLR or PLR.Articles assessed the OS or DFS of BC patients.

The criteria for exclusion were as following: Articles not focused on the prognosis of BC patients.Articles concerned on neither pretreatment NLR nor PLR.Reviews or editorials.Case reports or conference abstracts.Articles without data of interest (OS or DFS).

Articles with duplicate sample set, such as those published by same authors or departments, were picked out for further screening. In this case, only the articles with largest sample size or those published most recently were finally included in the present meta‐analysis. However, for those studies analyzed two or more independent sample sets such as training and validation cohorts, the cohorts were enrolled in this study and analyzed independently.

2.3. Data management and statistical analysis {#cam42281-sec-0009}
---------------------------------------------

The software of Endnote (version X8) was used for preliminary screening and sorting. Data were extracted from the enrolled literatures by two authors (Wanying Guo and Xin Lu) after reading full text intensively. The baseline information included full list of authors as well as affiliations, year of publication, geographical region, research centers, models of use, sample size, cut‐off values for NLR and PLR, mean or median ages, proportion of triple negative patients, indications for surgical treatment, follow‐up time, and treatment strategies. The hazard ratios (HRs) with 95% confidential intervals (CIs) were directly extracted from the tables or texts. However, in several studies, the HRs and 95% CIs were not shown directly. In such cases, the software of Engauge Digitizer (version 4.1) was used to extract HRs and 95% CIs by computing the Kaplan‐Meier graph.[11](#cam42281-bib-0011){ref-type="ref"}, [12](#cam42281-bib-0012){ref-type="ref"} The primary outcomes were pooled using the Cochrane Collaboration\'s Review Manager (version 5.3, Cochrane Collaboration, Oxford, UK).[13](#cam42281-bib-0013){ref-type="ref"} Random effect model was applied routinely only if no obvious heterogeneity was observed among the included literatures (*I* ^2^ \< 40%). Heterogeneity within studies was explored by using the chi‐square test with a P value of 0.10 for significance. Moreover, the heterogeneities were quantified using the *I* ^2^ statistics. Sensitivity analyses of main outcomes were conducted by using the software of Stata (version 12.0).[14](#cam42281-bib-0014){ref-type="ref"} The publication bias was investigated using funnel plots. Moreover, the symmetry properties of funnel plot was examined by using Begg and Egger tests.[15](#cam42281-bib-0015){ref-type="ref"}

2.4. Risk of bias assessment {#cam42281-sec-0010}
----------------------------

All the included studies were critically assessed for methodological quality by 2 researchers independently (Lu X and Guo WY) by using the Quality In Prognosis Studies tool. Each study was graded for the following domains: study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding, and statistical analysis and reporting. The risk of bias for each domain is graded as low (−), moderate (±), or high (+).

2.5. Subgroup analysis {#cam42281-sec-0011}
----------------------

To identify the sources of heterogeneity, subgroup analyses were conducted according to etiologies, geographical region, cut‐off values, and tumor stage. Subgroup of triple‐negative included BC patients with negatively expressed estrogen receptor, progesterone receptor, and HER2, while subgroup of HER2‐positve enrolled BC patients with positive HER2 expression. Patients from different continents were classified into Asia, America, and Europe subgroups respectively. Patients with early stage and metastatic tumors were analyzed in different subgroups. It was difficult to subgroup analysis which based on therapeutic strategies because of most of BC patients received surgical treatment as well as other treatments like adjuvant chemotherapy, endocrine therapy or trastuzumab therapy.

3. RESULTS {#cam42281-sec-0012}
==========

3.1. Characteristics of included studies {#cam42281-sec-0013}
----------------------------------------

Literature research identified 1215 records: 115 from PubMed, 296 from Embase, 313 from Web of Science, 15 from the Cochrane Library, and 436 from Scopus. Meanwhile, 4 studies were identified through references. As shown in Figure [1](#cam42281-fig-0001){ref-type="fig"}, after screening titles and abstracts, 362 duplications and an additional 781 studies were excluded. Full text of the remaining 76 studies were read rigorously. Thirty‐seven more were excluded: 7 were published by same centers, 10 enrolled duplicate patients, 6 were conference abstracts and 14 were without survival data. Finally, a total of 39 studies with 17079 patients were included in the present meta‐analysis.[8](#cam42281-bib-0008){ref-type="ref"}, [9](#cam42281-bib-0009){ref-type="ref"}, [10](#cam42281-bib-0010){ref-type="ref"}, [16](#cam42281-bib-0016){ref-type="ref"}, [17](#cam42281-bib-0017){ref-type="ref"}, [18](#cam42281-bib-0018){ref-type="ref"}, [19](#cam42281-bib-0019){ref-type="ref"}, [20](#cam42281-bib-0020){ref-type="ref"}, [21](#cam42281-bib-0021){ref-type="ref"}, [22](#cam42281-bib-0022){ref-type="ref"}, [23](#cam42281-bib-0023){ref-type="ref"}, [24](#cam42281-bib-0024){ref-type="ref"}, [25](#cam42281-bib-0025){ref-type="ref"}, [26](#cam42281-bib-0026){ref-type="ref"}, [27](#cam42281-bib-0027){ref-type="ref"}, [28](#cam42281-bib-0028){ref-type="ref"}, [29](#cam42281-bib-0029){ref-type="ref"}, [30](#cam42281-bib-0030){ref-type="ref"}, [31](#cam42281-bib-0031){ref-type="ref"}, [32](#cam42281-bib-0032){ref-type="ref"}, [33](#cam42281-bib-0033){ref-type="ref"}, [34](#cam42281-bib-0034){ref-type="ref"}, [35](#cam42281-bib-0035){ref-type="ref"}, [36](#cam42281-bib-0036){ref-type="ref"}, [37](#cam42281-bib-0037){ref-type="ref"}, [38](#cam42281-bib-0038){ref-type="ref"}, [39](#cam42281-bib-0039){ref-type="ref"}, [40](#cam42281-bib-0040){ref-type="ref"}, [41](#cam42281-bib-0041){ref-type="ref"}, [42](#cam42281-bib-0042){ref-type="ref"}, [43](#cam42281-bib-0043){ref-type="ref"}, [44](#cam42281-bib-0044){ref-type="ref"}, [45](#cam42281-bib-0045){ref-type="ref"}, [46](#cam42281-bib-0046){ref-type="ref"}, [47](#cam42281-bib-0047){ref-type="ref"}, [48](#cam42281-bib-0048){ref-type="ref"}, [49](#cam42281-bib-0049){ref-type="ref"}, [50](#cam42281-bib-0050){ref-type="ref"} Among them, 35 studies with 159 39 BC patients analyzed the effectiveness of NLR and 15 studies with 7949 patients analyzed PLR. The characteristics of the 39 included studies were summarized in Table [1](#cam42281-tbl-0001){ref-type="table"}.

![Flow diagram showing study retrieval and selection process.](CAM4-8-4135-g001){#cam42281-fig-0001}

###### 

Characteristics of included studies

  Study               Year   Country      Design, center                        Models      Endpoint    HRs        Sample size   Cut‐off                  Ages (Years)                Triple negative tumors (%)   Diagnosis                                 Follow‐up (months)   Therapies
  ------------------- ------ ------------ ------------------------------------- ----------- ----------- ---------- ------------- ------------------------ --------------------------- ---------------------------- ----------------------------------------- -------------------- -----------------------------------------
  Allan et al         2016   Costa Rica   Retrospective, single center          NLR & PLR   OS & DFS    Reported   172           NLR: 3; PLR: 250         54.2 ± 12.7                 34 (19.6)                    Nonmetastatic breast cancer               79.3 (2‐90)          Adjuvant chemotherapy
  Asano et al         2015   Japan        Retrospective, single center          NLR         OS & DFS    Reported   177           NLR: 3                   ≤56:87;\>56:90              61 (34.5)                    Early stage breast cancer                 40.8 (7.2‐72)        Neoadjuvant chemotherapy
  Asano et al         2016   Japan        Retrospective, single center          PLR         OS & DFS    Reported   177           PLR: 150                 ≤56:87;\>56:90              61 (34.5)                    Early stage breast cancer                 37.2 (1.2‐72)        Neoadjuvant chemotherapy + surgery
  Azab et al          2013   USA          Retrospective, single center          NLR & PLR   OS          Reported   437           NLR: 3.3; PLR: 185       63.6 ± 0.7                  NA                           Breast cancer with all stages             Mean: 60             Surgery or chemotherapy or radiotherapy
  Blanchette et al    2018   Canada       Retrospective, single center          PLR         OS & FFS    Reported   154           PLR: 185                 56 (47‐63)                  0 (0)                        HER2‐positive metastatic breast cancer    34 (6‐124)           Trastuzumab therapy
  Bozkurt et al       2015   Turkey       Retrospective, single center          NLR         OS & DFS    Reported   85            NLR: 2                   ≤50:57;\>50:28              85 (100)                     Early stage breast cancer                 NA                   Surgery + adjuvant chemotherapy
  Chae et al          2018   Korea        Retrospective, single center          NLR         DFS         Reported   87            NLR: 1.7                 45.8 ± 11.2                 87 (100)                     Early stage breast cancer                 Median: 57           Neoadjuvant chemotherapy + surgery
  Chen et al          2016   China        Retrospective, single center          NLR         DFS & CSS   Reported   215           NLR: 2.1                 46.41 ± 9.82                18 (8.4)                     TNM stage II‐III                          57.6 ± 27.1          Neoadjuvant chemotherapy + surgery
  Cho et al           2018   Korea        Retrospective, single center          NLR & PLR   DFS & CSS   Reported   661           NLR: 1.34; PLR: 185.5    52.7 ± 11.5                 117 (17.7)                   All TNM stages                            72 (1‐189)           Surgery
  Cihan et al         2014   Turkey       Retrospective, single center          NLR & PLR   OS & DFS    Reported   350           NLR: 3; PLR: 160         55.3 ± 0.3                  NA                           All TNM stages                            0.3‐112              Surgery + adjuvant therapies
  Dirican et al       2015   Turkey       Retrospective, single center          NLR         OS & DFS    Reported   1527          NLR: 4                   ≤35:92;36‐50:619;\>50:816   214 (14)                     All TNM stages                            30 (2‐75)            Surgery
  Ferroni et al       2018   Italy        Retrospective, Database               NLR         OS & DFS    Reported   475           NLR: 2                   57 ± 13                     57 (12)                      All TNM stages                            45.6 (3.12‐139.2)    Surgery
  Forget et al        2014   Belgium      Retrospective, Database               NLR         OS & DFS    Reported   425           NLR: 3.3                 25‐89                       NA                           Resectable breast cancer                  69.8 (53.5‐89.9)     Surgery
  Gunduz et al        2015   Turkey       Retrospective, single center          PLR         DFS         Reported   62            PLR: 200                 52 (24‐73)                  NA                           Advanced breast cancer                    Median: 48.4         Surgery + adjuvant chemotherapy
  Hernandez et al     2017   Spain        Retrospective, single center          NLR         OS & DFS    Reported   150           NLR: 3.3                 49.8 (28‐77)                38 (25.3)                    TNM stage I‐III                           24 (1‐144)           Neoadjuvant chemotherapy + surgery
  Hong et al          2016   China        Retrospective, single center          NLR         OS & DFS    Reported   487           NLR: 1.93                55 (28‐89)                  94 (19.2)                    Primary invasive breast cancer            Median: 55           Surgery
  Iwase et al         2017   Japan        Retrospective, single center          NLR         OS          Reported   89            NLR: 3                   50.9 ± 11.3                 24 (27)                      Recurrent breast cancer                   NA                   Chemotherapy
  Jia et al           2015   China        Retrospective, single center          NLR         OS & DFS    Reported   1570          NLR: 2                   48.9 ± 11.8                 225 (14.3)                   Operable breast cancer                    79 (4‐172)           Surgery
  Koh et al           2014   Korea        Retrospective, single center          NLR         OS & DFS    Reported   157           NLR: 2.25                44 (24‐71)                  0 (0)                        ER/PR(+) and HER2(−)                      21 (1‐108)           Neoadjuvant chemotherapy + surgery
  Koh et al           2015   Malaysia     Retrospective, single center          NLR & PLR   OS& DFS     Reported   1435          NLR: 4; PLR: 185         Median: 52                  208 (14.5)                   All TNM stages                            NA                   Surgery or chemotherapy or radiotherapy
  Krenn‐Pilko et al   2014   Austria      Retrospective, single center          PLR         OS & DFS    Reported   747           PLR: 292                 57.9 ± 12.2                 **NA**                       Nonmetastatic breast cancer               98 ± 29.2            Surgery
  Krenn‐Pilko et al   2016   Austria      Retrospective, single center          NLR         OS & DFS    Reported   747           NLR: 3                   58.1 ± 12.2                 **NA**                       Nonmetastatic breast cancer               Median: 106          Surgery
  Lee et al           2018   Korea        Retrospective, single center          NLR         OS & DFS    Reported   358           NLR: 3.16                Median: 51                  358 (100)                    Advanced triple‐negative breast cancer    NA                   Surgery
  Limori et al        2018   Japan        Retrospective, single center          NLR         OS          Reported   34            NLR: 3                   63 (44‐88)                  NA                           Stage IV breast cancer                    NA                   Endocrine therapy
  Liu et al           2016   China        Retrospective, single center          NLR & PLR   OS & DFS    Reported   318           NLR: 3; PLR: 147         45 (19‐71)                  161 (50.6)                   HR(−) nonmetastatic breast cancer         58.1 (5.9‐136.1)     Surgery
  Mando et al         2018   Argentina    Retrospective, single center          NLR         DFS         Reported   85            NLR: 2                   56 (44‐66)                  5 (5.9)                      Early stage breast cancer                 38.6 (29.4‐60.1)     Surgery
  Miyagawa et al      2018   Japan        Retrospective, single center          NLR         OS          Reported   59            NLR: 3                   34‐83                       12 (21.4)                    Metastatic breast cancer                  NA                   Chemotherapy
  Nakano et al        2014   Japan        Retrospective, single center          NLR         DFS & CSS   Reported   167           NLR: 2.5                 57.9 ± 10.9                 NA                           Operable breast cancer with stage I‐III   85.8 (19.8‐148.9)    Neoadjuvant chemotherapy or surgery
  Orditura et al      2016   Italy        Retrospective, single center          NLR         DFS         Reported   300           NLR: 1.97                ≤35:9;\>35:291              30 (10)                      Early stage breast cancer                 Median: 84           Surgery
  Pistelli et al      2014   Italy        Retrospective, single center          NLR         OS & DFS    Reported   90            NLR: 3                   53 (28‐79)                  90 (100)                     Early stage breast cancer                 53.8 (13.1‐95.2)     Surgery
  Qiu et al           2018   China        Retrospective, single center          NLR         OS & DFS    Reported   406           NLR: 2.85                44 (21‐75)                  406 (100)                    Early stage breast cancer                 54.3 (7.8‐126.5)     Surgery + chemotherapy
  Takeuchi et al      2017   Japan        Retrospective, single center          NLR & PLR   DFS         Reported   296           NLR: 2.06; PLR: 162.28   \<50:61;≥50:235             NA                           Localized breast cancer                   Median: 41           Surgery
  Takuwa et al        2018   Japan        Retrospective, single center          NLR         OS          Reported   171           NLR: 1.9                 59 (31‐89)                  NA                           Metastatic breast cancer                  44 (0‐217)           Multidisciplinary therapy
  Templeton et al     2018   Spain        Prospective, 65 GEICAM institutions   NLR         OS & DFS    Reported   1243          NLR: 1.35                50 (23‐76)                  107 (8.6)                    Early stage breast cancer                 Median: 120          Surgery + chemotherapy
  Ulas et al          2015   Turkey       Retrospective, two centers            NLR & PLR   OS & DFS    Reported   51            NLR: 2.38; PLR: 161.28   51.4 ± 10.4                 NA                           HER2‐positive early breast cancer         26 (6‐84)            Surgery + adjuvant chemotherapy
  Vernieri et al      2018   Italy        Retrospective, single center          NLR & PLR   OS          Reported   57            NLR: 2.5; PLR: 200       56 (33.7‐78.9)              57 (100)                     Metastatic breast cancer                  NA                   Chemotherapy
  Wariss et al        2017   Brazil       Retrospective, one center             NLR & PLR   OS          Reported   2288          NLR: 4; PLR: 150         55 (18‐98)                  301 (12.7)                   All TNM stages                            NA                   All kinds of therapies
  Yao et al           2014   China        Retrospective, one center             NLR & PLR   OS & DFS    Reported   608           NLR: 2.56; PLR: 107.64   52.4 ± 10.8                 98 (17.2)                    Operable breast cancer                    42 (8‐62)            Surgery
  Zhang et al         2016   China        Retrospective, one center             NLR         OS & DFS    Reported   162           NLR: 1.81                50.8 ± 10.6                 NA                           TNM stage I‐III                           NA                   Surgery

CSS, cancer‐specific survival; DFS, disease‐free survival; FFS, failure‐free survival; HRs, hazard ratios; N/A, not available; NLR, neutrophil‐to‐lymphocyte ratio; OS, overall survival; PLR, platelet‐to‐lymphocyte ratio; TNM, Tumor, node, metastases; GEICAM, Spanish Group for the Investigation of Breast Cancer Ages and Follow‐up periods were expressed as mean ± SD or median (range).

The bolds represent summary of subgroup analyses for OS and DFS.
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3.2. Overall and subgroup analysis for NLR {#cam42281-sec-0014}
------------------------------------------

Twenty‐eight studies comprising 142 64 BC patients investigated predicting role of NLR for OS. The pooled results shown that patients with elevated NLR prior treatment were associated worse prognosis compared to those with lower NLR (HR: 1.78; 95% CI: 1.49‐2.13; *P* \< 0.001). Twenty‐seven cohort studies containing 115 04 patients explored the prognostic role of NLR in predicting DFS. The results demonstrated that patients with elevated NLR were associated with poor DFS, with a HR of 1.60 (95% CI: 1.42‐1.96; *P* \< 0.001) (Figure [2](#cam42281-fig-0002){ref-type="fig"}).

![Forest plot of NLR in predicting OS (a) and DFS (b) of BC patients.](CAM4-8-4135-g002){#cam42281-fig-0002}

Results for subgroup analyses were shown in Table [2](#cam42281-tbl-0002){ref-type="table"}. The results of other subgroups displayed similar outcomes to overall result except subgroup of HER2‐positive and America. Six studies analyzed patients with HER2‐positively expressed showed that NLR was not significantly associated with OS (HR: 1.27; 95% CI: 0.94‐1.72; *P* = 0.12). In subgroup of America, the pooled result also showed no significant correlation between NLR with OS (HR: 1.91; 95% CI: 0.83‐4.37; *P* = 0.13). The results of subgroups for predicting DFS were similar to overall result. However, subgroup analyses based on tumor progression was unable to conduct due to insufficient data.

###### 

Subgroup analyses of NLR for OS and DFS

  Subgroups                   Independent cohorts   Sample size   HR\* (95% CI) (H/L\*)   *P* value      Study heterogeneity                     
  --------------------------- --------------------- ------------- ----------------------- -------------- --------------------- -------- -------- --------------
  **Overall survival**        **28**                **142 64**    **1.78 (1.49‐2.13)**    **\<0.0001**   **97.01**             **27**   **72**   **\<0.0001**
  Pathology                                                                                                                                      
  Triple‐negative             12                    2157          2.18 (1.75‐2.73)        \<0.0001       15.70                 11       30       0.15
  Her2‐positive               6                     1094          1.27 (0.94‐1.72)        0.12           8.19                  5        39       0.15
  Cut‐off value                                                                                                                                  
  \<3                         12                    5608          1.79 (1.33‐2.41)        0.0001         47.85                 11       77       \<0.0001
  ≥3                          16                    8656          1.79 (1.42‐2.24)        \<0.0001       44.85                 15       67       \<0.0001
  Tumor progression                                                                                                                              
  Early‐stage                 16                    6984          1.70 (1.33‐2.18)        \<0.0001       65.10                 15       77       \<0.0001
  Metastatic                  6                     768           2.17 (1.68‐2.81)        \<0.0001       2.27                  5        0        0.81
  Geographical region                                                                                                                            
  Asia                        18                    8180          1.79 (1.42‐2.25)        \<0.0001       71.50                 17       76       \<0.0001
  America                     3                     2897          1.91 (0.83‐4.37)        0.13           9.69                  2        79       0.008
  Europe                      7                     3187          1.65 (1.20‐2.27)        0.002          11.94                 6        50       0.06
  **Disease‐free survival**   **27**                **115 04**    **1.60 (1.42‐1.96)**    **\<0.0001**                                            
  Pathology                                                                                                                                      
  Triple‐negative             10                    1674          1.77 (1.44‐2.18)        \<0.0001       14.40                 9        38       0.11
  Her2‐positive               5                     881           1.41 (1.05‐1.89)        0.02           8.66                  4        54       0.07
  Cut‐off value                                                                                                                                  
  \<3                         17                    7190          1.67 (1.42‐1.96)        \<0.0001       34.16                 16       53       0.005
  ≥3                          10                    4313          1.50 (1.21‐1.86)        0.0003         17.63                 9        49       0.04
  Geographical region                                                                                                                            
  Asia                        18                    7817          1.57 (1.34‐1.83)        \<0.0001       37.75                 17       55       0.003
  America                     2                     257           1.61 (1.09‐2.85)        0.02           0.23                  1        0        0.63
  Europe                      7                     3430          1.75 (1.30‐2.35)        0.0002         13.92                 6        57       0.03

Abbreviations: CI\*, confidence interval; *df*\*, degrees of freedom; HR, Hazard Ratio; H, High group, L, Low group.

The bolds represent summary of subgroup analyses for OS and DFS.
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3.3. Overall and subgroup analyses for PLR {#cam42281-sec-0015}
------------------------------------------

As shown in Table [3](#cam42281-tbl-0003){ref-type="table"}, 12 studies with 6930 patients explored the prognostic role of PLR in predicting OS of patients with BC. The pooled outcome suggested that patients with higher PLR were associated with a significantly poor prognosis (HR: 1.32; 95% CI: 1.11‐1.57; *P* = 0.002). Eleven studies with 5013 patients investigated predicting role of PLR for DFS shown that patients with elevated PLR were associated with shorter DFS (HR: 1.43; 95% CI: 1.09‐1.86; *P* = 0.009) (Figure [3](#cam42281-fig-0003){ref-type="fig"}).

###### 

Subgroup analyses of PLR for OS and DFS

  Subgroups                   Independent cohorts   Sample size   HR\* (95% CI) (H/L\*)   *P* value   Study heterogeneity                     
  --------------------------- --------------------- ------------- ----------------------- ----------- --------------------- -------- -------- --------------
  **Overall survival**        **12**                **6930**      **1.32 (1.11‐1.57)**    **0.002**                                            
  Pathology                                                                                                                                   
  Triple‐negative             4                     727           1.54 (1.03‐2.33)        0.04        9.65                  3        69       0.02
  Her2‐positive               5                     894           1.18 (0.83‐1.70)        0.36        9.70                  4        59       0.05
  Cut‐off value                                                                                                                               
  \<185                       6                     3928          1.09 (0.97‐1.22)        0.15        3.94                  5        0        0.56
  ≥185                        6                     3002          1.81 (1.33‐2.46)        0.0001      14.04                 5        64       0.02
  Tumor progression                                                                                                                           
  Early‐stage                 6                     2209          1.26 (0.97‐1.63)        0.08        11.83                 5        58       0.04
  Metastatic                  2                     211           1.69 (1.27‐2.27)        0.0004      0.14                  1        0        0.71
  Geographical region                                                                                                                         
  Asia                        6                     3075          1.14 (1.02‐1.28)        0.02        5.23                  5        4        0.39
  America                     4                     3051          1.89 (1.13‐3.14)        0.01        17.88                 3        83       0.0005
  Europe                      2                     804           1.70 (1.10‐2.62)        0.02        0.25                  1        0        0.62
  **Disease‐free survival**   **11**                **5013**      **1.43 (1.09‐1.86)**    **0.009**   **44.24**             **10**   **77**   **\<0.0001**
  Pathology                                                                                                                                   
  Triple‐negative             1                     161           1.40 (0.97‐2.00)        0.07        NA                    NA       NA       NA
  Her2‐positive               3                     406           0.74 (0.42‐1.31)        0.30        5.75                  2        65       0.06
  Cut‐off value                                                                                                                               
  \<185                       6                     1936          1.28 (0.99‐1.66)        0.06        10.03                 5        50       0.07
  ≥185                        5                     3077          1.63 (0.86‐3.07)        0.13        32.74                 4        88       \<0.0001
  Geographical region                                                                                                                         
  Asia                        9                     4094          1.28 (0.98‐1.68)        0.07        34.19                 8        77       \<0.0001
  America                     1                     172           4.13 (1.60‐10.66)       0.003       N/A                   N/A      N/A      N/A
  Europe                      1                     747           2.02 (1.18‐3.46)        0.01        N/A                   N/A      N/A      N/A

Abbreviations: CI\*, confidence interval; *df*\*, degrees of freedom; HR, Hazard Ratio; H, High group, L, Low group; N/A, not available.

The bolds represent summary of subgroup analyses for OS and DFS.
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![Forest plot of PLR in predicting OS (a) and DFS (b) of BC patients.](CAM4-8-4135-g003){#cam42281-fig-0003}

Subgroup analyses shown there were no statistically significant correlation between PLR and OS in patients with HER2‐positive expression or patients with early stage tumor. Subgroup analysis based on cut‐off value suggested a value that more than 185 was better for PLR in predicting prognosis of BC patients (HR: 1.81; 95% CI: 1.33‐2.46; *P* \< 0.001). In subgroup analyses for PLR in predicting DFS, no significant association was found (Table [3](#cam42281-tbl-0003){ref-type="table"}).

3.4. Sensitivity analyses and publication bias {#cam42281-sec-0016}
----------------------------------------------

The sensitivity analyses was conducted to investigate the stabilities of the pooled HRs of OS and DFS by omitting enrolled studies in turn. The results showed that the pooled HRs did not alter significantly after eliminating the included studies in sequence which suggested the steady of our findings (Figure [4](#cam42281-fig-0004){ref-type="fig"}).

![Sensitivity analyses and funnel plots of OS and DFS for NLR (a, b and e, f) and PLR (c, d and g, h).](CAM4-8-4135-g004){#cam42281-fig-0004}

The funnel plots showed no obvious publication bias among the enrolled studies (studies distributed around the center line symmetrically). Moreover, 2 kinds of statistical tests further validated the dissymmetry of the funnel plot by using Egger\'s test and Begg\'s test (Table [4](#cam42281-tbl-0004){ref-type="table"}).

###### 

Assessment for publication bias

                Number of estimate   Z value   *P* for Begg\'s test   t      *P* for Egger\'s test
  ------------- -------------------- --------- ---------------------- ------ -----------------------
  NLR for OS    28                   1.10      0.272                  1.74   0.096
  NLR for DFS   27                   1.66      0.097                  1.20   0.241
  PLR for OS    12                   1.03      0.304                  1.31   0.220
  PLR for DFS   11                   1.40      0.161                  1.38   0.202

Abbreviations: DFS, disease‐free survival; NLR, neutrophil‐to‐lymphocyte ratio; OS, overall survival; PLR, platelet‐to‐lymphocyte ratio.
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4. DISCUSSION {#cam42281-sec-0017}
=============

Recently, more and more studies focused on correlation between inflammation and solid malignancies revealed that tumor initiation, progression, and metastasis were affected by host systemic inflammatory response as well as tumor microenvironment.[4](#cam42281-bib-0004){ref-type="ref"}, [51](#cam42281-bib-0051){ref-type="ref"}, [52](#cam42281-bib-0052){ref-type="ref"} Hence, we performed a meta‐analysis, including 39 studies comprising 17079 BC patients, to evaluate the prognostic role of NLR and PLR in predicting OS and DFS. A significant prognostic effect for NLR and PLR was found on OS and DFS after pooling results. High NLR level was associated with both poor OS as well as DFS for BC patients. Meanwhile, patients with elevated PLR were associated worse OS as well as higher risk of recurrence compared to those with decreased PLR level.

Although the underlying molecular mechanisms have not been adequately illuminated. Neutrophil was considered to be related to cancer‐associated inflammation with the potential mechanism of responding to the ectopic interleukin‐8 released in tumor proliferation, progression and metastasis.[53](#cam42281-bib-0053){ref-type="ref"} Moreover, cancer‐associated cytokines like tumor necrosis factor‐α and interleukin‐6 contribute to neutrophilia in solid cancers.[54](#cam42281-bib-0054){ref-type="ref"}, [55](#cam42281-bib-0055){ref-type="ref"} Neutrophilia inhibits the cytotoxic activity of immune cells like lymphocytes, natural killer cells and T cells which would counteract the anti‐tumor immune response.[56](#cam42281-bib-0056){ref-type="ref"}, [57](#cam42281-bib-0057){ref-type="ref"} A high platelet counts was considered to be related to metastasis of BC cells with the mechanism of contribution to lysophosphatidic acid‐dependent metastasis.[58](#cam42281-bib-0058){ref-type="ref"} Platelets could also promote tumor angiogenesis and stroma formation by secreting vascular endothelial growth factor and facilitating migration of inflammatory cells.[59](#cam42281-bib-0059){ref-type="ref"}, [60](#cam42281-bib-0060){ref-type="ref"} Loi et al found elevated lymphocytic infiltration in BC was associated with favorable prognosis, especially in those node‐positive and HER2‐negative BC.[61](#cam42281-bib-0061){ref-type="ref"} The lymphocytes played an important role in cell‐mediated anti‐tumor immune responses and tumor immunological surveillance.[62](#cam42281-bib-0062){ref-type="ref"}, [63](#cam42281-bib-0063){ref-type="ref"}, [64](#cam42281-bib-0064){ref-type="ref"}

In view of the heterogeneity of BC, subgroup analyses according to different subtypes like triple‐negative and HER2‐positive. The results shown a greater magnitude of association between NLR and OS in triple‐negative BC patients than in HER2‐positive ones. And negative prognostic effect was found for NLR and PLR in HER2‐positive BC patients. A previous meta‐analysis performed by Zhang et al included 11 studies and 1 conference abstract to evaluate the prognostic value of PLR in BC.[65](#cam42281-bib-0065){ref-type="ref"} Their process of extracting data were not rigorous enough that several HRs with 95% were not consistent with original researches.[10](#cam42281-bib-0010){ref-type="ref"}, [47](#cam42281-bib-0047){ref-type="ref"} The pooled results of our study were more credible and stable because of more rigorous in data extraction and subgroup analyses. Nonetheless, future prospective studies with large sample size were in need to confirm our outcomes especially the prognostic effect of NLR and PLR on HER2‐positive BC patients. Our subgroup analyses also suggested that a cut‐off value no less than 185 for PLR in predicting OS was more preferable.

Individualized therapy based on tumor‐associated biological characteristics and host circumstance was advocated in treatment strategies for BC. Several treatments such as surgical resection combined with adjuvant chemotherapy or neoadjuvant chemotherapy, endocrine therapy, and targeted therapy were optional for BC patients with different tumor stages. This study performed subgroup analysis based on tumor stage suggested comparative effect of NLR and PLR in predicting OS. The data were insufficient to conduct subgroup analysis based on treatment strategies.

To our knowledge, this was the most comprehensive meta‐analysis with largest sample size to estimate the prognostic role of PLR as well as NLR for BC. However, there were still several limitations should be taken into consideration when interpreting our findings. First, although there was no obvious publication bias, all the included studies were retrospectively designed. High proportion of retrospective individual studies would give rise to inherent bias inevitably. It would be preferable for future studies to design and collect data prospectively. Second, in the subgroup analysis of pathology, only triple‐negative and HER2‐positive BC patients were enrolled. Furthermore, all the included studies were written in English which would result in potential publication bias. Finally, future international multi‐center studies with larger sample size were in need to confirm our results.

Nevertheless, the present meta‐analysis was performed at an appropriate time as an adequate number of studies with sufficient data in a large patient cohort investigating the prognostic effect of NLR and PLR for BC patients have been accumulated, allowing evaluation through meta‐analysis. A meta‐analysis is considered to be a statistical inspection of scientific studies which is associated with higher evidence level than the individual studies themselves.[66](#cam42281-bib-0066){ref-type="ref"} Subgroup analyses were performed to minimize heterogeneity stemming from different BC‐specific subtypes, optional cut‐off values, geographical regions, and tumor stages.

In conclusion, this study suggested that elevated NLR and PLR were associated with poor OS as well as high risk of recurrence for BC patients. Subgroup analyses confirmed negative prognostic value of NLR and PLR for HER2‐positive BC patients. As easily accessible parameters, NLR and PLR should be identified as useful biomarkers in the management of BC.
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